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Hydrogen Sulﬁde Regulates Kr€uppel-Like Factor 5 Transcription
Activity via Speciﬁcity Protein 1 S-Sulfhydration at Cys664 to Prevent
Myocardial Hypertrophy
Guoliang Meng, MD, PhD; Yujiao Xiao, MD; Yan Ma, MSc; Xin Tang, MSc; Liping Xie, MD, PhD; Jieqiong Liu, MSc; Yue Gu, PhD;
Ying Yu, PhD; Chung-Min Park, PhD; Ming Xian, PhD; Xin Wang, MD, PhD; Albert Ferro, PhD, FRCP; Rui Wang, MD, PhD;
Philip K. Moore, PhD; Zhiren Zhang, MD, PhD; Hong Wang, MD, PhD; Yi Han, MD, PhD; Yong Ji, MD, PhD
Background-—Hydrogen sulﬁde (H2S) is a gasotransmitter that regulatesmultiple cardiovascular functions. Kr€uppel-like factor 5 (KLF5)
exerts diverse functions in the cardiovascular system. Whether and how H2S regulates KLF5 in myocardial hypertrophy is unknown.
Methods and Results-—In our study, hypertrophic myocardial samples in the clinic were collected and underwent histological and
molecular biological analysis. Spontaneously hypertensive rats and neonatal rat cardiomyocytes were studied for functional and
signaling responses to GYY4137, an H2S-releasing compound. Expression of cystathionine c-lyase, a principal enzyme for H2S
generation in heart, decreased in human hypertrophic myocardium, whereas KLF5 expression increased. After GYY4137
administration for 4 weeks, myocardial hypertrophy was inhibited in spontaneously hypertensive rats, as demonstrated by
improvement in cardiac structural parameters, heart mass, size of cardiac myocytes, and expression of atrial natriuretic peptide.
H2S diminished expression of KLF5 in myocardium of spontaneously hypertensive rats and in hypertrophic cardiomyocytes. H2S
also inhibits platelet-derived growth factor A promoter activity, decreased recruitment of KLF5 to the platelet-derived growth factor
A promoter, and reduced atrial natriuretic peptide expression in angiotensin II–stimulated cardiomyocytes, and these effects are
suppressed by KLF5 knockdown. KLF5 promoter activity and KLF5 expression was also reversed by H2S. H2S increased the S-
sulfhydration on speciﬁcity protein 1 in cardiomyocytes. Moreover, H2S decreased KLF5 promoter activity; reduced KLF5 mRNA
expression; attenuated speciﬁcity protein 1 binding activity with KLF5 promoter; and inhibited hypertrophy after speciﬁcity protein
1 mutated at Cys659, Cys689, and Cys692 but not Cys664 overexpression.
Conclusions-—These ﬁndings suggest that H2S regulates KLF5 transcription activity via speciﬁcity protein 1 S-sulfhydration at
Cys664 to prevent myocardial hypertrophy. ( J Am Heart Assoc. 2016;5:e004160 doi: 10.1161/JAHA.116.004160)
Key Words: atrial natriuretic peptide • hydrogen sulﬁde • Kr€uppel-like factor 5 •myocardial hypertrophy • speciﬁcity protein 1
• S-sulfhydration
H ypertension is a common cardiovascular disease and aleading cause of mortality worldwide. Myocardial
hypertrophy, structural remodeling, and extracellular matrix
accumulation are prominent in the left ventricle in the context
of hypertension, which constitutes an independent risk factor
for acute cardiovascular events such as myocardial ischemia
From the Key Laboratory of Cardiovascular Disease and Molecular Intervention (G.M., Y.X., Y.M., X.T., L.X., J.L., Y.G., Y.J.) and School of Pharmacy (Y.J.), Nanjing Medical
University, Nanjing, China; Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, China (G.M.); Department of Pathology, Jincheng People’s
Hospital, Jincheng, China (Y.X.); Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, Shanghai, China (Y.Y.); Department of Chemistry, Washington State University, Pullman, WA (C.-M.P., M.X.); Faculty of Life Sciences, The University of
Manchester, UK (X.W.); Cardiovascular Division, Department of Clinical Pharmacology, British Heart Foundation Centre of Research Excellence, Faculty of Life Sciences
and Medicine, King’s College London, London, UK (A.F.); Department of Biology, Laurentian University, Sudbury, Canada (R.W.); Department of Pharmacology, National
University of Singapore, Singapore (P.K.M.); Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Third Afﬁliated Hospital of Harbin Medical
University, Harbin, China (Z.Z.); Department of Pharmacology, Centers for Metabolic Disease Research, Cardiovascular Research, and Thrombosis Research, Temple
University School of Medicine, Philadelphia, PA (H.W.); Department of Geriatrics, First Afﬁliated Hospital of Nanjing Medical University, Nanjing, China (Y.H.).
Correspondence to: Yong Ji, MD, PhD, Key Laboratory of Cardiovascular Disease and Molecular Intervention, School of Pharmacy, Nanjing Medical University, 101
Longmian Road, Nanjing, Jiangsu 211166, China. E-mail: yongji@njmu.edu.cn and Yi Han, MD, PhD, Department of Geriatrics, First Afﬁliated Hospital of Nanjing
Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, China. E-mail: hanyi79@163.com
Received July 6, 2016; accepted August 12, 2016.
ª 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is
not used for commercial purposes.
DOI: 10.1161/JAHA.116.004160 Journal of the American Heart Association 1
ORIGINAL RESEARCH







or infarction and heart failure.1 To date, however, the
pathogenetic mechanisms underlying myocardial hypertrophy
in this situation remain incompletely elucidated.
The Kr€uppel-like factor (KLF) family exerts diverse func-
tions in the cardiovascular system.2 It is noted that mice with
deﬁcient KLF5 expression (KLF5+/ mice) exhibit decreased
inﬂammatory vascular response and cardiac hypertrophy
induced by reduced angiotensin II (Ang II).3
Hydrogen sulﬁde (H2S) has long been known as a toxic gas,
but the physiological importance of endogenously produced
H2S has become increasingly recognized in recent years, and
it is now accepted as the third “gasotransmitter” after nitric
oxide and carbon monoxide.4 Accumulating evidence sug-
gests that H2S inﬂuences a wide range of physiological and
pathological processes, especially in the cardiovascular
system, including modulation of blood vessel tone and
cardioprotection, for which cystathionine c-lyase (CSE) is
the main enzyme for H2S generation.
5,6
The cardiovascular protective effects of H2S include
homeostatic regulation of blood pressure and decreased
production of myocardial reactive oxygen species, suggesting
that H2S may protect against hypertrophy.
7,8 Several reports
suggest that H2S is able to regulate activity of transcriptional
factor to perform its physiological or pathophysiological
effects. H2S inhibited nuclear factor jB activation in oxidized
low-density lipoprotein–stimulated macrophage.9 H2S stabi-
lized hypoxia-inducible factor 1a and increased hypoxia-
responsive gene expression in colon.10 H2S also enhanced the
nuclear translocation of signal transducer and activator of
transcription 3.11 Nevertheless, the pathogenesis of myocar-
dial hypertrophy is complex, and the precise mechanisms by
which H2S may protect against it remain unclear.
To date, no information exists about the potential role of
H2S in modulating activity of transcriptional factor KLF5 in the
regulation of myocardial hypertrophy. The aims of the present
study were to examine whether H2S can attenuate myocardial
hypertrophy and to elucidate the possible role and detailed
mechanism of KLF5 in this protective effect.
Methods and Materials
Collection and Analysis of Human Myocardium
and Blood Samples
Human myocardium samples of hypertension were collected
during cardiac surgical procedures of cardiac valve replace-
ment and classiﬁed into those with no myocardial hypertrophy
(n=21, control group) and those with myocardial hypertrophy
(n=26, hypertrophy group) according to echocardiographic
ﬁndings prior to surgery. Blood samples were also collected.
Myocardial samples were subjected to histological or
molecular biological analysis. H2S concentration in plasma
and myocardium was also measured. Human study conformed
to the principles outlined in the Declaration of Helsinki. The
study protocol was approved by the ethics committee of First
Afﬁliated Hospital of Nanjing Medical University (approval no.
2014-SRFA-128). Written informed consent was obtained
from all patients.
Measurement of Plasma Ang II
Plasma Ang II from the patients was measured using iodine I
125 Ang II radioimmunoassay kits (North Institute of Biolog-
ical Technology). Each measurement was performed in
duplicate and averaged for statistics analysis. According to
the level of Ang II, samples with myocardial hypertrophy were
classiﬁed into those with normal Ang II (53–115 pg/mL) and
high Ang II (>115 pg/mL).
Immunohistochemistry
Human myocardium sections ﬁxed in paraformaldehyde were
incubated with anti-KLF5 and anti-CSE antibodies overnight at
4°C, washed 3 times, and incubated with afﬁnity-puriﬁed
biotinylated IgG for 1 hour at room temperature. Sections
incubated with PBS instead of primary antibody served as
negative controls. They were washed again and overlaid with
streptavidin–biotin–peroxidase complex for 1 hour at room
temperature (Maixin Bio). After a ﬁnal wash, labeling was
performed with 3,30-diaminobenzidine (Maixin Bio). Counter-
staining was then performed with Mayer’s hematoxylin.
Measurement of H2S in Plasma and Myocardium
H2S in plasma was measured using an H2S-speciﬁc micro-
electrode (ISO-H2S-2; World Precision Instruments) connected
to a free radical analyzer (TBR4100; World Precision Instru-
ments).12 The sensor was set to the 10-nA range and the
poise voltage to +150 mV. Prior to initiation of the experi-
ments, the sensor was polarized and calibrated by adding 4
aliquots of the Na2S stock solution at ﬁnal concentrations of
0.5, 1.0, 2.0, 4.0, and 8.0 lmol/L. Concentrations of H2S in
the samples were calculated using a standard curve of Na2S,
and the level in patients was normalized to the level in those
without hypertrophy.
H2S in myocardium was determined in tissue homoge-
nates.6 Brieﬂy, the assay mixture (500 lL) contained 460 lL
tissue homogenate, 20 lL L-cysteine (10 mmol/L), and 20 lL
pyridoxal 50-phosphate (2 mmol/L). Incubations were carried
out in tightly sealed vials. After incubation (37°C, 30 min-
utes), concentration of H2S was measured using an H2S-
speciﬁc microelectrode, as described earlier.
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Male spontaneously hypertensive rats (SHRs) and Wistar-
Kyoto rats aged 12 weeks were obtained from Shanghai SLAC
Laboratory Animal Co. Ltd (Shanghai, People’s Republic of
China). Normotensive Wistar-Kyoto rats served as controls
(Wistar-Kyoto group, n=10), and age-matched SHRs were
randomly divided into 4 groups (n=10 per group) that were
assigned different dosages of GYY4137, a water-soluble H2S-
releasing compound (in mg/kg per day): 0 (SHR group), 10
(GYY10 group), 25 (GYY25 group), or 50 (GYY50 group).
GYY4137 was given by intraperitoneal injection once daily
over a 4-week period.
Animal experiments were performed in accordance with
the US National Institutes of Health Guidelines for Care and
Use of Laboratory Animals. This study was approved by the
Committee on Animal Care of Nanjing Medical University
(approval no. NJMU-ERLAUA-20110112).
Echocardiography
After 4 weeks of treatment, cardiac geometry and function were
evaluated after anesthesia under light isoﬂurane (1–2%) anes-
thesia using an echocardiography system (Visual Sonics Vevo
2100; VisualSonics) equipped with a 12-MHz linear-array
transducer. Two-dimensional images were obtained in the
parasternal long- and short-axis views and apical 2- and 4-
chamber views. Thicknesses of the interventricular septum and
left ventricular (LV) posterior wall and LV end-systolic and end-
diastolic diameters were measured from the 2-dimensional
targeted M-mode echocardiographic tracings. LV ejection
fraction and fractional shortening were derived by goal-directed,
diagnostically driven software. Diastolic function was assessed
by the ratio between the peak of initial inﬂow velocity (E wave)
and the atrial contraction (A wave) of transmitral ﬂow (E/A).
Recording of Hemodynamic Parameters
After echocardiography, anesthesia was induced using 3%
isoﬂurane in 3 L/min of oxygen and maintained using 2.5%
isoﬂurane per liter of O2. Arterial pressureswere assessed using
a Millar Tip catheter (Millar Instruments Inc) that was inserted
into the right carotid artery and was connected to a pressure
transducer. After an equilibration period of 30 minutes, systolic
blood pressure, diastolic blood pressure, and mean arterial
pressure were recorded. Then the catheter was advanced into
the LV cavity. LV end-systolic pressure and maximal positive LV
pressure development were determined from systolic LV
performance. Diastolic LV function was represented by LV
end-diastolic pressure, and maximal LV pressure decay was
calculated. Arterial and LV pressures were recorded simultane-
ously using a data acquisition system (MedLab-U/4C501,
Nanjing Medease Science and Technology).
Assessment of Cardiac Index
After completion of hemodynamic measurements, rats were
euthanized with an overdose of isoﬂurane (5% isoﬂurane with
2 L/min oxygen). Heart weight, body weight, heart mass
index (heart weight:body weight ratio), LV weight, LV mass
index (LV weight:body weight ratio) and LV weight:tibia length
ratio were measured and calculated as indices of cardiac
hypertrophy.
Neonatal Cardiomyocyte Culture and Treatment
Sprague-Dawley rats aged 1 to 3 days were euthanized by
decapitation. Hearts were removed immediately. The ventri-
cles were separated from the atria, trisected, and digested
with 0.25% trypsin (Beyotime),at 37°C for 7 to 10 cycles until
completely digested. All supernatants from each cycle except
the ﬁrst were pooled. DMEM (Wisent Inc) with 10% FBS
(Wisent Inc) at a volume equal to that of supernatants was
added to terminate digestion, cells were pelleted, and the
pellet was resuspended in DMEM containing 10% FBS,
100 U/mL penicillin, and 100 lg/mL streptomycin. Bromod-
eoxyuridine (0.1 mmol/L; Sigma-Aldrich) was also added to
prevent nonmyocyte proliferation. The cell suspension was
incubated for 4 hours at 37°C in a humidiﬁed 5% CO2
incubator to separate cardiomyocytes and ﬁbroblasts. The
cells from 5 rats were planted in a 6-well plate or other culture
plate with equal area. Density of cardiomyocytes was
adjusted to 49105 cells/mL.
After neonatal rat cardiomyocytes had been cultured for 2 to
3 days, the medium was changed to DMEM supplemented with
0.5% FBS for 24 hours. Serum-starved cells were then
pretreated with different concentrations of GYY4137 (12.5,
25.0, or 50.0 lmol/L) or NaHS (100 lmol/L) for 4 hours
before being incubatedwith Ang II (100 nmol/L; Sigma-Aldrich)
for a further 24 hours. ZYJ1122 (a structural analogue of
GYY4137 lacking sulfur) and “spent” GYY4137 (GYY4137
dissolved for 72 hourswith no deﬁnitive H2S release) were used
as controls in the experiment.6,7,13 After undergoing the various
treatments outlined earlier, digested cells were photographed
at high magniﬁcation using an inverted microscope.
Plasmid or siRNA Transfection
Cultured neonatal rat cardiomyocytes were serum deprived
for 2 hours and then transfected with rat KLF5-speciﬁc siRNA
(50-AACCCGGAUCUGGAGAAGCGA-30), nonspeciﬁc control
siRNA (50-GCGCGCUUUGUAGGAUUCG-30), speciﬁcity protein
1 (SP-1) siRNA or nonspeciﬁc control (Santa Cruz Biotech-
nology, Dallas, TX); wild-type SP-1 or SP-1 mutated at Cys659,
Cys664, Cys689, and Cys692 to Ala (Haibio, Shanghai,
China); wild-type CSE plasmid (provided by R.W.) using the
Lipofectamine 2000 or Lipofectamine 3000 reagent
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(Invitrogen), according to the manufacturer’s protocol. After
24 hours, the cells were pretreated with GYY4137 for
4 hours, followed by Ang II (100 nmol/L) for 24 hours.
Luciferase Reporter Assay
Neonatal rat cardiomyocytes were incubated in 12-well plates
in DMEM supplemented with 10% FBS for 24 hours. Cells in
each dish were transfected at 70% conﬂuence with 1 lg KLF5
or platelet-derived growth factor A (PDGF-A; Zoonbio Biotech-
nology Co. Ltd) promoter–luciferase fusion plasmid and 0.1 lg
of pRL-TK reporter plasmid (control reporter) using Lipofec-
tamine 2000 reagent (Invitrogen). At 24 hours after transfec-
tion, cells were treated with GYY4137 (50 lmol/L) or vehicle
for 4 hours, followed by Ang II stimulation for 24 hours. Cells
were harvested in cell lysis buffer, and the assay was performed
with a dual luciferase reporter assay system (Promega),
according to the manufacturer’s instructions. Fireﬂy luciferase
activity was normalized to that of control reporter. The relative
luciferase activities compared with the luciferase activities of
pRL-TK were determined in triplicate.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation assays were performed using
the Pierce Agarose ChIP Kit (Thermo Fisher Scientiﬁc),
according to the manufacturer’s recommendations. In brief,
neonatal rat cardiomyocytes treated as described earlier were
cross-linked with 1% formaldehyde for 10 minutes and
sonicated 5 to 10 times each for 10 seconds at 4°C in lysis
buffer (150 mmol/L NaCl, 25 mmol/L Tris pH 7.5, 1% Triton
X-100, 0.1% SDS, 0.5% deoxycholate) to reduce the average
DNA length to 0.4 to 0.5 kb. The samples were then
precleared with protein A agarose/salmon sperm DNA for
30 minutes at 4°C, followed by overnight incubation at 4°C
with antibodies speciﬁc for KLF5 or SP-1 or normal rabbit IgG
(as a negative control). Immune complexes were precipitated
with protein A agarose for 1 hour. Precipitated genomic DNA
was ampliﬁed by real-time polymerase chain reaction (PCR)
with primers. Potential KLF5-binding sites on the PDGF-A
promoter region were ampliﬁed with the primer pair 50-
TGTCTGCAAAACACGGACGGTG-30 (sense) and 50- TTGATGTA-
CAGGTGCATTCC-30 (antisense). Potential SP-1-binding sites
on the KLF5 promoter region were ampliﬁed with the primer
pair 50-GACCTGCACACCATATAGCA-30 (sense) and 50-
CACTCTCTCCACCGCTCATA-30 (antisense).
Measurement of SP-1 Binding Activity
SP-1 binding activity was measured using an electrophoretic
mobility shift assay kit (Thermo Fisher Scientiﬁc), following
the manufacturer’s instructions. In brief, nuclear extracts
from cardiomyocytes were prepared using a Nuclear and
Cytoplasmic Extraction Reagents Kit (Thermo Fisher Scien-
tiﬁc). Nuclear extracts (8 lg) were incubated with a
reaction system (109 binding buffer 2 lL, poly(deoxyi-
nosinic-deoxycytidylic) acid 1 lL, 50% glycerol 1 lL, 1% NP-
40 1 lL, KCl 1 lL, MgCl2 1 lL). An SP-1 oligonucleotide
probe was added to the samples. The nucleotide sequence
of the oligonucleotides used for electrophoresis mobility
Table 1. Sequences of Primers Used
Gene Sense Primer Antisense Primer
Rat KLF2 50- ACTTGCAGCTACACCAACTG-30 50- CTGTGACCCGTGTGCTTG-30
Rat KLF3 50- TCATGTACACCAGCCACCTG-30 50- CATGTACACCAGCCACCTG-30
Rat KLF4 50- TCAAGAGCTCATGCCACCGG-30 50- CTCGCCTGTGTGAGTTCGCA-30
Rat KLF5 50- AGCTCACCTGAGGACTCATA-30 50- GTGCGCAGTGCTCAGTTCT-30
Rat KLF6 50- CCTTACAGATGCTCTTGGGA-30 50- GGAGAAACACCTGTCACAGT-30
Rat KLF9 50- TGGCTGTGGGAAAGTCTATGG-30 50- CTCGTCCGAGCGCGAGAACT-30
Rat KLF10 50- TACTGATGTCTTCACCTACAG-30 50- GTACCACAAACATGACCGTG-30
Rat KLF11 50-AACAGAATCACCTTAGCAGAG-30 50-AACAGCCCAGAGACCATGG-30
Rat KLF15 50-GATGAGTTGTCACGGCACC-30 50-CACTGCGCTCAGTTGATGG-30
Rat ANP 50-GCT TCC GGG ATG AAA ACG TC-30 50-ACC AAT CCA TTG CCG ACT ATG-30
Rat CSE 50-GAGGGAAGTCTTGGAAATGGC-3 50-CGCAACATTTCATTTCCCG-30
Human KLF5 50-CACTACTGCGATTACCCTG-30 50-GGTCTGTCATTTGAGGGAG-30
Human ANP 50- TCTGCCCTCCTAAAAAGCAA-30 50- ATCACAACTCCATGGCAACA -30
Human CSE 50- GACTCTACATGTCCGAATGG -30 50- AACCTGTACACTGACGCTTCA-30
18S 50- AGTCCCTGCCCTTTGTACACA -30 50- CGATCCGAGGGCCTCACTA -30
DOI: 10.1161/JAHA.116.004160 Journal of the American Heart Association 4






















Figure 1. Level of H2S in human plasma and myocardium and expression of ANP, CSE, and KLF5 in human myocardium. Myocardium or
blood samples were collected from patients with hypertension, with or without left ventricular hypertrophy. A, Plasma Ang II concentration. B,
H2S concentration in plasma (as percentage of control). C, H2S level in myocardium. D, Histological examination of human myocardium by HE
staining (bar=100 lm) and measurement of CSE and KLF5 expression by immunohistochemistry staining (bar=50 lm). E, Quantiﬁcation of
ANP mRNA expression by real-time PCR. F–J, Measurement of CSE and KLF5 expression by real-time PCR and Western blotting. Sample size:
(A–C, E–G) n=21 in control group, n=12 in the group with hypertrophy with normal Ang II, n=14 in the group with hypertrophy with high Ang II;
(D) n=6; (H–J) n=12 in control group, n=6 in the group with hypertrophy with normal Ang II, n=6 in the group with hypertrophy with high Ang II.
**P<0.01 vs control (without hypertrophy). Ang II indicates angiotensin II; ANP, atrial natriuretic peptide; CSE, cystathionine c-lyase; H2S,
hydrogen sulﬁde; HE, hematoxylin and eosin; KLF5, Kr€uppel-like factor 5; PCR, polymerase chain reaction.
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shift assay was 50-AATCGATCGGGGCGGGGCGAGC-30. Syn-
thetic double-strand oligonucleotides used in gel mobility
shift assays were biotin labeled at the 50 end (Invitrogen). A
probe without a biotin label as a nonspeciﬁc competitor
was added to the mixture, followed by incubation at room
temperature for 20 minutes prior to adding the labeled
probe. Tubes were incubated for another 20 minutes at
room temperature. DNA–protein complexes were resolved
on nondenaturing acrylamide gels and transferred to a
nylon membrane (Amersham Pharmacia Biotech). The
proteins were ultraviolet cross-linked twice for 1 minute
each time. Protein bands were visualized by enhanced
chemiluminescence.
Quantitative Real-Time PCR
Total RNA was extracted using Trizol reagent (Takara). RNA
(500 ng) was added as a template to reverse transcriptase
reactions carried out using a PrimeScript RT Master Mix Kit
(Takara). Quantitative real-time PCR was carried out with
resulting cDNAs using SYBR Green Premix (Takara) and an ABI
7500 Real Time PCR System (Applied Biosystems). Experi-
mental cycle threshold values were normalized to 18S, and
relative mRNA expression was calculated versus a reference
sample. Each sample was run and analyzed in triplicate
(Table 1).
Western Blotting Analysis
Protein samples were separated by SDS-PAGE and transferred
onto a polyvinylidene ﬂuoride membrane (Millipore). After
blocking at room temperature in 5% vol/vol nonfat milk with
TBST buffer (Tris-HCl 10 mmol/L, NaCl 120 mmol/L, Tween-
20 0.1%, pH 7.4) for 2 hours, membranes were incubated
overnight with the appropriate primary anti-KLF5, tubulin, and
lamin B1 (1:1000; Santa Cruz Biotechnology); anti–SP-1
(1:2000; Abcam); anti–ANP (1:1000; Abcam); anti-CSE
(1:1000; Bioworld); and anti-GAPDH (1:5000; Sigma-Aldrich)
at 4°C and then incubated with horseradish peroxidase–
conjugated secondary antibody at room temperature for
2 hours. Protein bands were visualized by enhanced chemi-
luminescence.
“Tag-Switch” Method for the Detection of Protein
S-Sulfhydration on SP-1
SP-1 S-sulfhydration was detected with the “Tag-Switch”
method.14 Brieﬂy, after treatment, neonatal cardiomyocytes
were resuspended in HEN buffer (250 mmol/L HEPES,
50 mmol/L NaCl, 1 mmol/L EDTA, 0.1 mmol/L neocuproine,
1% NP-40) supplemented with protease inhibitors and lysed by
5920-second cycles of ultrasonication. Cell lysate was mixed
with 50 mmol/L MSBT-A (a water-soluble methylsulfonyl ben-
zothiazole), incubated 1 hour at 37°C, and then desalted on
Micro Bio-Spin P-6 gel columns (Bio-Rad Laboratories). The
protein of SP-1 was pulled down with immunoprecipitation and
then treated with 20 mmol/L biotin-linked cyanoacetate in PBS
containing 2.5%SDS for 1 hour at room temperature. The excess
of biotin-linked cyanoacetate was removed by passing the
samples through Micro Bio-Spin P-6 gel columns. Prior to
electrophoresis, samples were mixed with nonreducing Laemmli
buffer (Bio-Rad Laboratories) and boiled at 95°C for 1 minute.
Proteinswere resolved on10%SDSpolyacrylamide gels and then
transferred on polyvinylidene ﬂuoride membrane. Membrane
was blockedwith 5% nonfat milk for 1 hour at room temperature
and incubated overnight with horseradish peroxidase–labeled
mouse monoclonal anti–biotin antibody. The signal of protein S-
sulfhydration was visualized using Pierce ECL reagent.
Statistical Analysis
All data are expressed as meanSEM. Data with normal
distribution were analyzed by t test or 1-way analysis of
variance followed by the Bonferroni post hoc test, as
appropriate. Data without normal distribution were ana-
lyzed by Kruskal–Wallis test (Stata 13.0 software; Stata-
Corp). Values of P<0.05 were considered statistically
signiﬁcant.
Figure 2. Effect of GYY4137 on blood pressure in
SHRs. Male SHRs and WKY rats aged 12 weeks
were given GYY4137 by intraperitoneal injection at
doses of 10 mg/kg per day (GYY10), 25 mg/kg
per day (GYY25), or 50 mg/kg per day (GYY50) for
4 weeks. SBP, DBP, and MAP were measured from
the left carotid artery after 4 weeks of treatment.
n=10. **P<0.01 vs WKY rats; #P<0.05, ##P<0.01
vs SHRs. DBP indicates diastolic blood pressure;
MAP, mean arterial pressure; SBP, systolic blood
pressure; SHR, spontaneously hypertensive rat;
WKY rat, Wistar-Kyoto rat.
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Hypertrophic Human Myocardium Exhibits
Decreased CSE but Enhanced KLF5 Expression
According to the plasma level of Ang II, patients were
classiﬁed into those with Ang II levels that were normal (53–
115 pg/mL) or high (>115 pg/mL) (Figure 1A). H2S con-
centrations in both plasma and myocardium were lower in
patients exhibiting myocardial hypertrophy (regardless of
Ang II level) than in those without hypertrophy (Figure 1B
and 1C). The presence or absence of myocardial hypertrophy
according to echocardiograms was further conﬁrmed by
cardiomyocyte size (Figure 1D) and level of atrial natriuretic
peptide (ANP; as an indicator of myocardial hypertrophy)
mRNA expression in myocardium (Figure 1E). All of the
hypertrophic myocardium samples, regardless of Ang II level,
Figure 3. Effect of GYY4137 on myocardial hypertrophy in SHR and Ang II-induced neonatal rat cardiomyocytes. A, Male
SHR and WKY rats at 12 weeks of age were given GYY4137 by intraperitoneal injection at doses of 10 mg/kg per day
(GYY10), 25 mg/kg per day (GYY25) or 50 mg/kg per day (GYY50) for 4 weeks. Representative 2-D M-mode
echocardiograms in rat hearts after 4 weeks’ treatment. B through D, Quantitative analysis of IVS and LVPW thickness,
LVESD, LVEDD, EF, and FS by echocardiography (n=8). E, Histological examination with hematoxylin and eosin staining of
myocardium. Bar=6.3 lm. F, Cardiomyocyte area was then calculated by morphometric analysis (n=10). G–I, HW, HMI,
LVMI, and LVW/TL were measured and calculated (n=10). J, Quantiﬁcation of ANP expression by real-time polymerase
chain reaction (n=8). K, Quantiﬁcation of ANP expression by Western blotting (n=3). L, Neonatal rat cardiomyocytes were
pretreated with GYY4137 (12.5, 25, and 50 lmol/L) for 4 hours followed by Ang II (100 nmol/L) for a further 24 hours.
Cells were digested, and cell surface area was calculated (n=4). M and N, Quantiﬁcation of ANP mRNA and protein
expression (n=4). Untreated cells served as control. For (A–K), **P<0.01 vs WKY; #P<0.05, ##P<0.01 vs SHR. For (L–N),
**P<0.01 vs con; #P<0.05, ##P<0.01 vs cells treated with Ang II alone. Ang II, angiotensin II; ANP, atrial natriuretic peptide;
EF, ejection fraction; FS, fractional shortening; HMI, heart mass index; HW, heart weight; IVS, interventricular septum;
LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass
index; LVPW, left ventricular posterior wall; LVW/TL, left ventricular weight/tibia length ratio; SHR, spontaneously
hypertensive rat; WKY rat, Wistar-Kyoto rat.
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exhibited higher expression of KLF5 but lower expression of
CSE, as assessed by immunohistochemistry, real-time PCR,
and Western blotting (Figure 1D, 1F–1J). Consequently, we
investigated the effect of H2S supplementation on myocar-
dial hypertrophy and the possible involvement of KLF5 in its




Figure 4. Effect of GYY4137 on cardiac diastolic function in SHRs. Male SHRs and WKY rats aged 12 weeks were given GYY4137 by
intraperitoneal injection at doses of 10 mg/kg per day (GYY10), 25 mg/kg per day (GYY25), or 50 mg/kg per day (GYY50) for 4 weeks. Cardiac
diastolic function was assessed by the ratio of the peak of initial inﬂow velocity (E wave) and the atrial contraction (A wave) of the transmitral
ﬂow (E/A). A, WKY rats. B, SHRs. C, GYY10. D, GYY25. E, GYY50. F, Quantitation of E/A ratio after GYY4137 treatment for 4 weeks. n=8. SHR
indicates spontaneously hypertensive rat; WKY rat, Wistar-Kyoto rat.
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H2S Improves Myocardial Structure and Cardiac
Function
Invasive arterial blood pressure measurement showed that
SHRs aged 12 weeks treated with GYY4137 at 25 or 50 mg/kg
per day for 4 weeks (but not 10 mg/kg per day) displayed
decreased systolic blood pressure, diastolic blood pressure,
and mean arterial pressure (Figure 2). M-mode echocardiogra-
phy demonstrated that both interventricular septum and LV
posterior wall thickness in SHRs aged 16 weeks were greater
than those of age-matched normotensiveWistar-Kyoto controls
and were attenuated by 4-week treatment with the 3 doses of
GYY4137 (Figure 3A and 3B). LV end-diastolic diameter was
increased after GYY4137 administration with no discernible
effects on LV end-systolic diameter, LV ejection fraction,
fractional shortening (Figure 3C and 3D), or E/A ratio (Fig-
ure 4). There were no signiﬁcant differences in hemodynamic
parameters between groups except for LV end-systolic pres-
sure (Table 2), suggesting that H2S does not affect cardiac
systolic or diastolic function in SHRs aged 16 weeks.
H2S Attenuates Myocardial Hypertrophy in SHR
and Ang II–Induced Neonatal Rat Cardiomyocyte
Hypertrophy
Hematoxylin and eosin staining revealed cardiomyocytes in
SHRs to be enlarged, and this was prevented by GYY4137
treatment for 4 weeks (Figure 3E and 3F). Compared with the
Wistar-Kyoto group, heart weight, heart mass index, LV mass
index, and LV weight:tibia length ratio (all indices of hyper-
trophy) were increased in the untreated SHR group, and these
changes were prevented by H2S (Figure 3G through 3I). ANP
was expressed to a greater degree at both the mRNA and
Table 2. Effect of GYY4137 Treatment for 4 Weeks on Hemodynamic Parameters in SHRs (n=10)
Parameter WKY SHR GYY10 GYY25 GYY50
LVESP, mm Hg 1049 1858** 1808 1619†† 14810††
LVEDP, mm Hg 3.321.64 5.212.31 5.772.34 5.022.22 4.291.51
dp/dtmax, mm Hg/s 7301801 8012916 76741039 7235990 7077927
dp/dtmax, mm Hg/s 6734835 7102872 7062890 6422553 6282843
s, ms 8.581.37 12.021.40** 11.031.56 10.711.55 10.351.48
dP/dtmax indicates maximal left ventricular pressure decay; dP/dtmax, maximal positive left ventricular pressure development; GYY10, GYY4137 10 mg/kg/day; GYY25, GYY4137 25
mg/kg/day; GYY50, GYY4137 50 mg/kg/day; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; SHR, spontaneously hypertensive rat; WKY,
Wistar-Kyoto rat.
**P<0.01 vs WKY, ††P<0.01 vs SHR analyzed with 1-way analysis of variance followed by Bonferroni post hoc test.
Figure 5. Effect of ZYJ1122 and “spent” GYY4137 on Ang II-stimulated neonatal rat cardiomyocytes
hypertrophy. A, Neonatal rat cardiomyocytes were pre-treated with GYY4137 (50 lmol/L), ZYJ1122
(50 lmol/L) or “spent” GYY4173 (50 lmol/L of GYY4137 dissolved in cell culture medium for 72 hours)
for 4 hours followed by Ang II (100 nmol/L) for a further 24 hours. Cells were digested and cell surface
area was calculated. B, Quantiﬁcation of ANP mRNA by real-time PCR. Untreated cells served as control
(con). n=4. **P<0.01 vs con; #P<0.05, vs cells treated with Ang II alone. Ang II indicates angiotensin II;
ANP, atrial natriuretic peptide.
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protein levels in myocardium from SHRs, and this increase in
expression was attenuated by GYY4137 treatment for
4 weeks (Figure 3J and 3K).
Cultured neonatal rat cardiomyocytes were induced into
hypertrophy with Ang II, as shown histologically by
increased cardiomyocyte surface area and enhanced ANP
Figure 6. Effect of GYY4137 on KLF5 expression in Ang II–stimulated neonatal rat cardiomyocytes. A, Neonatal rat cardiomyocytes were
pretreated with GYY4137 (50 lmol/L) for 4 hours before incubation with Ang II (100 nmol/L) for a further 24 hours. Quantiﬁcation of KLF
mRNA by real-time PCR. B, Quantiﬁcation of KLF5 mRNA expression by real-time PCR. C, Quantiﬁcation of KLF5 protein expression by Western
blotting. D, PDGF-A promoter luciferase activity was measured. E, Chromatin fragments for ChIP assays were immunoprecipitated with anti-KLF5
antibody. Precipitated DNA was ampliﬁed by real-time PCR with primers spanning the PDGF-A promoter region. A–E, n=4. **P<0.01 vs cells not
undergoing any drug treatment; #P<0.05, ##P<0.01 vs cells treated with Ang II alone. F, After rat KLF5-speciﬁc siRNA (KLF5 siRNA) or NC siRNA
transfection for 48 hours, KLF5 protein expression was measured with Western blotting (n=4). **P<0.01 vs NC. G, After siRNA transfection for
24 hours, cells were pretreated with GYY4137 (50 lmol/L) for 4 hours followed by Ang II (100 nmol/L) stimulation for 24 hours. PDGF-A
promoter luciferase activity was measured. Four independent experiments were performed. H, Quantiﬁcation of ANP mRNA expression by real-
time PCR. G and H, n=4. *P<0.05, **P<0.01 vs cells not undergoing any drug treatment (with corresponding siRNA transfection), ##P<0.01 vs
cells treated with Ang II alone (with corresponding siRNA transfection). Ang II indicates angiotensin II; ANP, atrial natriuretic peptide; ChIP,
chromatin immunoprecipitation; IgG, immunoglobulin G; KLF, Kr€uppel-like factor; NC, nonspeciﬁc control; PCR, polymerase chain reaction;
PDGF-A, platelet-derived growth factor A.
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mRNA and protein expression; these changes were all
inhibited by pretreatment with GYY4137 (12.5–50 lmol/L)
(Figure 3L–3N). Because 50 lmol/L GYY4137 produced the
most profound effects in these parameters, this concentra-
tion was used in the following experiments. To exclude the
inﬂuence of structure of GYY4137 on the attenuated
responses to hypertrophy, ZYJ1122 (a structural analogue
of GYY4137 lacking sulfur) and “spent” GYY4137 (GYY4137
dissolved for 72 hours with no deﬁnitive H2S release) were
used in the experiment. In addition, we found that only
Figure 7. Effect of GYY4137 on KLF5 expression in SHR. A, Male SHRs and WKY rats aged 12 weeks
were given GYY4137 by intraperitoneal injection at doses of 10 mg/kg per day (GYY10), 25 mg/kg per day
(GYY25) or 50 mg/kg per day (GYY50) for 4 weeks. Quantiﬁcation of KLF5 mRNA in myocardium by real-
time polymerase chain reaction. B, Quantiﬁcation of KLF5 protein in myocardium by Western blotting. n=4
to 8. *P<0.05, **P<0.01 vs WKY; #P<0.05, ##P<0.01 vs SHR. KLF5 indicates Kr€uppel-like factor 5; SHR,
spontaneously hypertensive rat; WKY rat, Wistar-Kyoto rat.
Figure 8. Effect of CSE overexpression and NaHS on Ang II–stimulated neonatal rat cardiomyocytes hypertrophy and KLF5 expression. A,
After WT CSE was transfected for 24 hours, neonatal rat cardiomyocytes were stimulated with Ang II (100 nmol/L) for 24 hours. Cells were
digested, and cell surface area was calculated. B and C, Quantiﬁcation of ANP and KLF5 mRNA by real-time PCR. D, Neonatal rat cardiomyocytes
were pretreated with NaHS (100 lmol/L) for 4 hours followed by Ang II (100 nmol/L) for a further 24 hours. Cells were digested, and cell
surface area was calculated. E and F, Quantiﬁcation of ANP and KLF5 mRNA by real-time PCR. n=4. Untreated cells served as control. **P<0.01
vs control; ##P<0.01 vs cells treated with Ang II alone. Ang II indicates angiotensin II; ANP, atrial natriuretic peptide; CSE, cystathionine c-lyase;
KLF5, Kr€uppel-like factor 5; PCR, polymerase chain reaction; WT, wild type.
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GYY4137—not ZYJ1122 or “spent” GYY4137—was able to
decrease cardiocyte area and ANP mRNA expression in Ang
II–stimulated neonatal rat cardiomyocytes (Figure 5).
H2S Diminishes KLF5 Expression Both In Vitro
and In Vivo
Quantitative analysis for KLF mRNA expression indicated
that mRNA expression of KLF5 was increased and that of
KLF11 was decreased in neonatal rat cardiomyocytes after
Ang II stimulation. The increased KLF5 expression, but not
the decreased KLF11 expression, was reversed by GYY4137
pretreatment (Figure 6A). Moreover, H2S diminished KLF5
mRNA and protein expression in Ang II–stimulated car-
diomyocytes (Figure 6B and 6C), whereas no alteration in
KLF5 expression was detected if cardiomyocytes were
treated with GYY4137 alone. GYY4137 administered for
4 weeks exerted a similar attenuating effect on KLF5
expression in myocardium of SHRs (Figure 7A and 7B). It is
noted that both CSE overexpression (endogenously increas-
ing H2S) and NaHS (another traditional H2S donor) also
decreased cardiocyte area and reduced mRNA expression
of ANP and KLF5 in Ang II–stimulated cardiomyocytes
(Figure 8A through 8F).
H2S Suppresses Ang II–Stimulated Neonatal Rat
Cardiomyocyte Hypertrophy in a KLF5-Dependent
Manner
Ang II increased PDGF-A promoter activity and enhanced the
recruitment of KLF5 to the PDGF-A promoter, which was
decreased after GYY4137 coincubation (Figure 6D and 6E).
KLF5 siRNA attenuated the effect of GYY4137 on decreasing
PDGF-A promoter activity and ANP mRNA expression (Fig-
ure 6F through 6H). Moreover, there was no signiﬁcant
difference on CSE mRNA expression if KLF5 was knocked
down (Figure 9A). These data suggest that H2S suppresses
Ang II–stimulated cardiomyocyte hypertrophy in a KLF5-
dependent manner.
H2S Attenuates KLF5 Transcriptional Activation
in Ang II–Stimulated Neonatal Rat
Cardiomyocytes
Luciferase (Luc) reporter assays revealed higher KLF5
promoter (2300/+236) activity with Ang II stimulation,
and GYY4137 reversed this effect (Figure 10A). In a series of
deletion constructs at 2300/+236, 363/+236, and 67/
+236, the attenuating effects of GYY4137 on KLF5 promoter
activity were observed in 2300 Luc, 363 Luc, and 67
Luc, respectively; however, GYY4137-induced inhibition of
KLF5 promoter activity was abolished in 32 Luc (Fig-
ure 10B). It appears that an important site between 67 and
32 bp upstream of the KLF5 promoter sequence is respon-
sible for the attenuating effect of H2S on KLF5 transcription.
Interestingly, the putative SP-1 binding site (50-GGCGGG -30) is
present in this region of the KLF5 promoter. Electrophoresis
mobility shift assay suggested that GYY4137 decreased
binding activity between SP-1 and DNA (Figure 10C and
10D), and chromatin immunoprecipitation assay conﬁrmed
that GYY4137 decreased SP-1 binding activity to the KLF5
promoter, which was enhanced after Ang II stimulation
(Figure 10E). Moreover, the attenuating effect of GYY4137
on KLF5 promoter activity and KLF5 mRNA expression was
weakened after SP-1 protein knockdown (Figure 10F through
10H). Taken together, our results suggest that H2S decreases
SP-1 binding to the KLF5 promoter and attenuates KLF5
transcriptional activity in Ang II–stimulated cardiomyocytes.
As a transcription factor, KLF5 exerts its potential biological
activity only once it enters the nucleus to bind with target
Figure 9. Effect of KLF5 siRNA or mutated SP-1 on CSE expression. A, After rat KLF5-speciﬁc siRNA or
NC siRNA transfection for 48 hours, CSE mRNA was measured with real-time PCR. B, After plasmid
transfection of WT SP-1 or mutated SP-1 at Cys659, Cys664, Cys689, or Cys692 for 48 hours, CSE mRNA
was measured with real-time PCR (n=4). CSE indicates cystathionine c-lyase; KLF5, Kr€uppel-like factor 5;
NC, nonspeciﬁc control; PCR, polymerase chain reaction; SP-1, speciﬁcity protein 1; WT, wild type.
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genes. After Ang II stimulation for 24 hours, we found that
KLF5 protein expression in the nuclei of cardiomyocytes was
increased, and GYY4137 attenuated this increase, with no
discernible change in cytoplasm (Figure 10I).
H2S Sulfhydrated SP-1 at Cys664 to Regulate
KLF5 Transcription Activity and Prevent
Myocardial Hypertrophy
We found stronger S-sulfhydration on SP-1 after GYY4137
administration in neonatal rat cardiomyocytes (Figure 11A)
and myocardium of SHRs (Figure 11B). According to the
structure and bioinformatics analysis of SP-1, there were 11
cysteine residues on SP-1, 4 of which (at 659, 664, 689,
and 692) located into the domain to bind with KLF5
promoter. Next, SP-1 mutated at Cys659, Cys664, Cys689,
or Cys692 to Ala (C659A, C664A, C689A or C692A), or
wild type was transfected into neonatal rat cardiomyocytes.
GYY4137 still enhanced S-sulfhydration on SP-1 after
overexpression of wild-type SP-1 or mutated SP-1 at
Cys659, Cys689 or Cys692 but not at Cys664 overexpres-
sion (Figure 11C). GYY4137 was able to attenuate KLF5
Figure 10. Effect of GYY4137 on KLF5 transcriptional activity in neonatal rat cardiomyocytes. A and B, Neonatal rat cardiomyocytes were
pretreated with GYY4137 (50 lmol/L) for 4 hours before incubation with Ang II (100 nmol/L) for a further 24 hours. KLF5 promoter activity was
determined using a dual-Luc reporter assay system. C andD, Electrophoresismobility shift assaywas performedwith a DNA probe harboring the SP-
1 site. E, Chromatin fragments for ChIP assays were immunoprecipitated with anti–SP-1 antibody. Precipitated DNA was ampliﬁed by real-time
polymerase chain reaction with primers spanning the KLF5 promoter region. F, After rat SP-1–speciﬁc siRNA or NC siRNA transfection for 48 hours,
SP-1 protein expression was measured. **P<0.01 vs NC. G and H, After siRNA transfection for 24 hours, cells were pretreated with GYY4137
(50 lmol/L) for 4 hours followed byAng II (100 nmol/L) stimulation for 24 hours. KLF5 promoter luciferase activity (G) andKLF5mRNAexpression
(H) were measured. I, KLF5 expression in cytoplasm and nucleus from cardiomyocytes was measured. Untreated cells served as control (n=4). A–E
and G–I, **P<0.01 vs control; #P<0.05, ##P<0.01 vs cells treated with Ang II alone. Ang II indicates angiotensin II; ChIP, chromatin
immunoprecipitation; IgG, immunoglobulin G; KLF5, Kr€uppel-like factor 5; Luc, luciferase; NC, nonspeciﬁc control; SP-1, speciﬁcity protein 1.
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promoter activity and mRNA expression in Ang II–stimulated
cardiomyocytes after SP-1–wild type, SP-1–C659A, SP-1–
C689A, or SP-1–C692A but not SP-1–C664A overexpres-
sion (Figure 11D and 11E). Chromatin immunoprecipitation
assay conﬁrmed that GYY4137 could decrease SP-1 binding
activity to the KLF5 promoter, which was enhanced after
Ang II stimulation but not in mutated SP-1 at Cys664A
overexpression (Figure 11F through 11J). Moreover,
GYY4137 inhibited hypertrophy, represented as reduced
ANP mRNA expression, after SP-1 mutated at Cys659,
Cys689, and Cys692 but not at Cys664 (Figure 11K). No
signiﬁcant difference was noted on CSE mRNA expression if
Figure 11. GYY4137 sulfhydrated SP-1 at Cys664 to regulate KLF5 transcription activity and to prevent myocardial hypertrophy. A, Neonatal
rat cardiomyocytes were incubated with GYY4137 (50 lmol/L) for 24 hours. SP-1-SSH was detected with the “Tag-Switch” method. B, Male
SHRs aged 12 weeks were given GYY4137 by intraperitoneal injection at doses of 50 mg/kg per day (GYY50) for 4 weeks. SP-1-SSH in
myocardium was detected with the Tag-Switch method. C, After plasmid transfection of WT SP-1 or mutated SP-1 at Cys659, Cys664, Cys689 or
Cys692 for 48 hours, SP-1-SSH was detected with the Tag-Switch method. D and E, After plasmid transfection of WT SP-1 or mutated SP-1 for
24 hours, cells were pretreated with GYY4137 (50 lmol/L) for 4 hours followed by Ang II (100 nmol/L) stimulation for 24 hours. KLF5
promoter luciferase activity (D) and KLF5 mRNA expression (E) were measured. F–J, Chromatin fragments for ChIP assays were
immunoprecipitated with anti–SP-1 antibody. Precipitated DNA was ampliﬁed by real-time polymerase chain reaction with primers spanning the
KLF5 promoter region. K, ANP mRNA expression was measured. Untreated cells served as control (n=4). **P<0.01 vs control; #P<0.05,
##P<0.01 vs cells treated with Ang II alone. Ang II indicates angiotensin II; ANP, atrial natriuretic peptide; ChIP, chromatin immunoprecipitation;
IgG, immunoglobulin G; IP, immunoprecipitation; KLF5, Kr€uppel-like factor 5; SHR, spontaneously hypertensive rat; SP-1, speciﬁcity protein 1;
SSH, S-sulfhydration; WT, wild type.
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wild-type or mutated SP-1 was transfected into cardiomy-
ocytes (Figure 9B).
Discussion
In the present study, we found that H2S levels in both plasma
and myocardium and CSE mRNA and protein expression levels
in myocardium were decreased in SHRs (Figure 12) and in
patients with myocardial hypertrophy, regardless of Ang II
level. These data suggested that the impaired H2S/CSE
system contributes to hypertrophy rather than Ang II.
Moreover, we found greater KLF5 mRNA and protein expres-
sion in hypertrophic myocardium from patients. These data tie
in well with our ﬁndings in rodents and raise the possibility
that H2S supplementation might be a clinically useful
therapeutic strategy in the future for attenuating cardiac
hypertrophy.
The role, if any, of H2S on myocardial hypertrophy has
previously been entirely unclear. NaHS has been reported to
suppress cardiac hypertrophy, possibly by modifying expres-
sion of Cx43 in rats with abdominal aortic coarctation.15 In
rats with isoproterenol-induced heart failure, NaHS protects
against myocardial hypertrophy by suppressing local renin
production.6; however, NaHS treatment for 3 months was not
found to reduce myocardial hypertrophy in a previous study
on SHRs.17 Divergent effects of H2S on myocardial hypertro-
phy may be explained by different types of H2S donors used in
such studies, different treatment durations, different animal
models, different ages, or a combination of these factors.
GYY4137, an H2S slow-releasing compound, was used in our
present study. When incubated in aqueous buffer (pH 7.4,
37°C), GYY4137 released H2S, climbed for 15 minutes, and
then plateaued at 75 minutes. After administration (intra-
venous or intraperitoneal) of GYY4137 to anesthetized rats,
plasma H2S concentration was increased at 30 minutes and
remained elevated over the 180-minute time course of the
experiment.7 We found that GYY4137 at doses of 10, 25, and
50 mg/kg per day attenuated myocardial hypertrophy in
SHRs; however, high blood pressure is a predominant factor
for the development of myocardial hypertrophy, and blood
pressure also decreases in SHRs treated with H2S.
7,18
Moreover, H2S is an endothelium-derived hyperpolarizing
factor, activating potassium channels to relax vascular
smooth muscle.19 Nevertheless, we found that, at low dose,
GYY4137 also attenuated myocardial hypertrophy without any
discernible antihypertensive effect in our study, suggesting
Figure 12. Effect of GYY4137 on the CSE/H2S system in SHRs. Male SHRs and WKY rats aged 12 weeks
were given GYY4137 by intraperitoneal injection at doses of 10 mg/kg per day (GYY10), 25 mg/kg per day
(GYY25), or 50 mg/kg per day (GYY50) for 4 weeks. A, Plasma H2S concentration. B, H2S in myocardium. C
and D, CSE expression as quantiﬁed by real-time polymerase chain reaction and Western blotting (n=6 to
8). **P<0.01 vs WKY rats; #P<0.05, ##P<0.01 vs SHRs. CSE indicates cystathionine c-lyase; H2S, hydrogen
sulﬁde; SHR, spontaneously hypertensive rat; WKY rat, Wistar-Kyoto rat.
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that the inhibitory effect of H2S on myocardial hypertrophy is
created, at least in part, through a blood pressure–indepen-
dent mechanism.
The KLF family of gene regulatory proteins is composed of
transcription factors that are implicated in many biological
processes, including proliferation, apoptosis, differentiation,
development, survival, and responses to external stress.2 The
primary KLF knockout phenotype includes cardiovascular
development abnormalities and higher susceptibility to injury
or cardiac failure, which suggests that KLF plays an important
regulatory role in the cardiovascular system.20,21 We hypoth-
esized that KLF might be responsible for the attenuation of
myocardial hypertrophy in response to H2S. We ﬁrst used
real-time PCR to determine whether H2S alters expression of
KLF family members. In our study, KLF11 expression was
impaired after Ang II stimulation in cardiomyocytes. KLF11
plays important roles in transforming growth factor b–
mediated cell growth and differentiation.22 Knockdown of
KLF11 potentiates basal and transforming growth factor b–
stimulated endothelin-1 expression in human endothelial
cells.22 In our study, however, the reduction in KLF11 could
not be restored by H2S, suggesting that KLF11 is not involved
in its protective effect on cardiomyocyte hypertrophy. More-
over, GYY4137 pretreatment only attenuated KLF5 mRNA
levels in the presence of Ang II stimulation. Consequently, we
focused on KLF5 in subsequent experiments.
KLF5 is a key regulator of cardiovascular remodeling.23
Heterozygous KLF5 knockout mice (KLF5+/) show dimin-
ished levels of arterial wall thickening, angiogenesis, cardiac
hypertrophy, and interstitial ﬁbrosis in response to stress.3 In
cultured cardiac ﬁbroblasts, Ang II increases expression of
KLF5 and PDGF-A, which controls tissue remodeling.3
Haploinsufﬁciency of KLF5 suppresses cardiac ﬁbrosis and
hypertrophy elicited by moderate-intensity pressure over-
load.24 It has also been reported previously that KLF5 can
interact with many other transcription factors (eg, c-Jun,
retinoic acid receptor a, CREB binding protein, PPAR-d) and
can activate various gene promoters such as a non–muscle-
type myosin heavy chain gene SMemb, plasminogen activator
inhibitor 1 , inducible nitric oxide synthase, PDGF-A, early
growth response 1, and vascular endothelial growth factor
receptors, at least in vitro, and thereby regulate the expres-
sion of many genes.25 In our study, the attenuating effect of
H2S on PDGF-A promoter activity and ANP mRNA expression
was weakened after KLF5 knockdown, suggesting that H2S
might act on a transcriptional element and suppress PDGF-A
promoter activity and cardiomyocyte hypertrophy in a KLF5-
depended manner.
KLF5 can also be regulated by a variety of transcription
factors and nuclear receptors, such as retinoic acid receptor
a, nuclear factor jB, PPAR-c, and p300.26,27 In our study, we
found that H2S can decrease SP-1 binding to the KLF5
promoter and thus suppress KLF5 expression. There are
abundant exposed cysteine groups in the structure of SP-1,
and it is possible that H2S may target SP-1 by S-sulfhydration.
Several reports found that S-sulfhydration is a newly deﬁned
posttranslational modiﬁcation and plays an important role in
regulating (mostly inhibiting) protein activity and physiological
effects.14,28–30 We found that there was stronger S-sulfhydra-
tion on SP-1 after GYY4137 incubation. In addition, GYY4137
regulated KLF5 transcriptional activity and inhibited hypertro-
phy after SP-1 mutated at Cys659, Cys689, and Cys692 but
not Cys664 overexpression. This suggests that sulfhydration
of SP-1 at Cys664 by H2S might be one of the detailed
mechanisms to suppress KLF5 transcription activity and thus
inhibit progression of myocardial hypertrophy (Figure 13).
In conclusion, this study provides evidence that H2S
increases SP-1 sulfhydration at Cys664 to regulate KLF5
transcription activity to prevent the development of myocar-
dial hypertrophy. These data highlight a novel role for KLF5 in
the protective effect of H2S on myocardial hypertrophy. An
H2S-related compound may be a useful therapeutic strategy in
clinical conditions associated with excessive hypertension
and myocardial hypertrophy in the future.
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Figure 13. Schematic depicting the proposed signal mecha-
nism by which H2S attenuates myocardial hypertrophy. H2S
sulfhydrates SP-1 at Cys664 to attenuate SP-1 binding activity
with KLF5 promoter, decreases KLF5 expression, and then
reduces KLF5 binding activity with PDGF-A promoter to inhibit
myocardial hypertrophy. H2S, hydrogen sulﬁde; KLF5, Kr€uppel-like
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